Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sumitomo Dainippon Acquires Asian Rights to Poxel's Diabetes Drug in $300 Million Agreement

publication date: Oct 30, 2017

Japan's Sumitomo Dainippon Pharma announced a $300 million deal to develop Poxel's novel type 2 diabetes treatment in Japan, China and eleven other SE Asian countries. Poxel, a French biopharma, has completed Phase II testing of Imeglimin, a treatment for mitochondrial dysfunction, in the US, Europe and Japan. Sumitomo plans to begin a Phase III trial in Japan before the end of the year. Japan is expected to be the drug's second largest global market after the US. The two companies did not estimate China's market size for Imeglimin. More details....

Stock Symbols: (TSE: 4506) (Euronext: POXEL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022